Healthcare tech company Omnicell (NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was less impressive, coming in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 27.1% above analysts’ consensus estimates.
Industrial technology solutions provider EnPro Industries (NYSE:NPO) announced better-than-expected revenue in Q1 CY2025, with sales up 6.1% year on year to $273.2 million. On the other hand, the company’s full-year revenue guidance of $0.04 at the midpoint came in 100% below analysts’ estimates. Its non-GAAP profit of $1.90 per share was 14% above analysts’ consensus estimates.
Electrical safety company Atkore (NYSE:ATKR) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 11.5% year on year to $701.7 million. Its non-GAAP profit of $2.04 per share was 19.2% above analysts’ consensus estimates.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 7.4% year on year to $458.4 million. Its non-GAAP profit of $0.33 per share was 38.3% above analysts’ consensus estimates.
Government and sustainable technology solutions company KBR (NYSE:KBR) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 13% year on year to $2.06 billion. On the other hand, the company’s full-year revenue guidance of $8.9 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $0.98 per share was 13.7% above analysts’ consensus estimates.
Technology real estate company Offerpad (NYSE:OPAD) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 43.7% year on year to $160.7 million. Next quarter’s revenue guidance of $175 million underwhelmed, coming in 1.4% below analysts’ estimates. Its non-GAAP loss of $0.54 per share was in line with analysts’ consensus estimates.
Online fashion resale marketplace ThredUp (NASDAQ:TDUP) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.5% year on year to $71.29 million. The company expects next quarter’s revenue to be around $73.5 million, close to analysts’ estimates. Its non-GAAP loss of $0.04 per share was $0.02 above analysts’ consensus estimates.
Diner restaurant chain Denny’s (NASDAQ:DENN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.5% year on year to $111.6 million. Its non-GAAP profit of $0.08 per share was in line with analysts’ consensus estimates.
Maritime transportation company Matson (NYSE:MATX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 8.3% year on year to $782 million. Its non-GAAP profit of $2.18 per share was 3.8% below analysts’ consensus estimates.
Medical device company Artivion (NYSE:AORT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 1.6% year on year to $98.98 million. The company’s full-year revenue guidance of $429 million at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.06 per share was $0.02 above analysts’ consensus estimates.
Toy manufacturing and entertainment company (NASDAQ:MAT) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.1% year on year to $826.6 million. Its non-GAAP loss of $0.03 per share was 70.4% above analysts’ consensus estimates.
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.
Security systems manufacturer Napco (NASDAQ:NSSC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 10.8% year on year to $43.96 million. Its non-GAAP profit of $0.30 per share was 11.7% above analysts’ consensus estimates.
Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors.
Snow and ice equipment company Douglas Dynamics (NYSE:PLOW) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 20.3% year on year to $115.1 million. Its non-GAAP profit of $0.09 per share was significantly above analysts’ consensus estimates.
The USD/JPY pair declined for a fifth consecutive day, touching 145.25, as the US dollar faced sustained pressure following Moody’s decision to downgrade the US credit rating.
Analog chips maker onsemi (NASDAQ:ON) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 22.4% year on year to $1.45 billion. The company expects next quarter’s revenue to be around $1.45 billion, close to analysts’ estimates. Its non-GAAP profit of $0.55 per share was 9.6% above analysts’ consensus estimates.
ONESPAN INC (NASDAQ:OSPN) offers strong earnings growth, high profitability, and a reasonable valuation, making it a potential pick for GARP investors following Peter Lynch's principles.
